
FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR
Key Takeaways
- FDA cleared secukinumab 150 mg for PMR, expanding an IL-17A–targeted monoclonal antibody beyond psoriasis and psoriatic arthritis into a glucocorticoid-sparing PMR strategy.
- REPLENISH randomized 381 relapsing PMR patients to secukinumab 300 mg, 150 mg, or placebo for 52 weeks, all with a standardized 24-week prednisone taper.
The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.
Today, the FDA
Secukinumab is a fully human monoclonal antibody that selectively inhibits IL-17A, a cytokine that contributes to the joint and surrounding tissue inflammation typical of PMR.2 It is already approved worldwide to treat adults with psoriatic arthritis and moderate to severe plaque psoriasis, among other
“Patients with PMR are at increased risk of poor outcomes related to steroids, and the prospect of months or years of additional steroids is disheartening,” John Stone, MD, MPH, professor of medicine at Harvard Medical School and global principal investigator for the REPLENISH trial, said in a statement. “For too long, treatment options beyond glucocorticoids have been limited. In the phase 3 REPLENISH trial, secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment.”1
REPLENISH Trial Doubles Sustained Remission in PMR
The trial randomized 381 patients with recently relapsed PMR 1:1:1 to receive secukinumab 300 mg (SEC-300), secukinumab 150 mg (SEC-150), or placebo for 52 weeks, with all patients also receiving a 24-week prednisone taper.2 The study met its primary end point of sustained remission at week 52.1
At the week 52 mark, sustained remission was observed in 41.2% (95% CI, 32.8%-49.7%) of patients in the SEC-300 group, 40.6% (95% CI, 32.2%-49.0%) of those in the SEC-150 group, and 20.4% (95% CI, 13.6%-27.2%) of those in the placebo group (P < .001 for the comparison of each secukinumab dose with placebo).2
Secondary end points included the proportion of patients who achieved complete sustained remission at 52 weeks, the adjusted annual cumulative steroid dose, and the time to first use of escape or rescue treatment through 52 weeks.1 Complete sustained remission was achieved by 24.5% of patients in the SEC-150 group vs 4.7% in the placebo group, and the mean adjusted annual cumulative glucocorticoid dose was 1683.2 mg vs 2093.0 mg, respectively.2
Safety Profile and the Burden of Long-Term Steroid Use
Secukinumab’s safety profile remained consistent with that of its prior approvals.1 Serious adverse events occurred in 15.9% of patients in the SEC-150 group and 14.2% in the placebo group. Hypersensitivity reactions and fungal infections were more common with secukinumab, and 1 patient in the SEC-150 group died of cryptococcal meningitis, which investigators considered potentially related to treatment.2
PMR is the second most common idiopathic inflammatory
“For more than a decade, [secukinumab] has helped redefine what’s possible for people living with immune-mediated diseases, delivering meaningful outcomes across multiple conditions,” Victor Bultó, president, US, Novartis, said in a press release. “With this approval in PMR, our 11th US indication for [secukinumab], we are expanding those benefits to a community that has had limited treatment options for far too long. This milestone reflects our commitment to continually investigate where our medicines can help patients most, extending the impact of proven innovations to new areas of significant unmet need.”1
References
1. Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR). News release. Novartis. November 17, 2026. Accessed November 17, 2026.
2. Stone JH, Buttgereit F, Saraux A, et al. Phase 3 trial of secukinumab in polymyalgia rheumatica. N Engl J Med. 2026;395(7):637-647. doi:10.1056/NEJMoa2602567
Related to this article








